This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ultram

Johnson & Johnson

Drug Names(s): tramadol hydrochloride, Tramal (Japan), NS-315

Description: Tramadol hydrochloride is a centrally acting synthetic opioid analgesic. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to µ-opioid receptors and weak inhibition of re-uptake of norepinephrine and serotonin.

Deal Structure: Tramadol hydrochloride was originally developed by Gruenenthal.

Tramadol is under license by Johnson & Johnson from Gruenenthal.

Grunenthal and Labopharm
In October 2009, Labopharm completed a distribution and supply agreement with Grunenthal GmbH for its twice-daily tramadol acetaminophen formulation for a number of countries in Europe.

Under the terms of the agreement, Grunenthal has the exclusive right to market and sell Labopharm's twice-daily tramadol-acetaminophen formulation in a number of European countries. Labopharm will supply Grunenthal with unpackaged tablets and will receive a fixed transfer price inclusive of gross margin. Labopharm will receive 3.5 million Euros on signature and up to 4 million Euros in milestone payments upon achievement of certain regulatory and product reimbursement approvals prior to the launch of the product.

Nippon Shinyaku and Labopharm
In April 2010, Nippon Shinyaku and Labopharm concluded a license...See full deal structure in Biomedtracker

Partners: Grünenthal GmbH Nippon Shinyaku Co., Ltd. Endo International plc Pfizer Inc.


Ultram News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug